Myocardial infarction (MI) is the main complication of coronary artery disease (CAD). Recently, a locus tagging the GUCY1A3 gene has been shown to be genome-wide significantly associated with CAD [1] . GUCY1A3 encodes for the α 1 -subunit of the soluble guanylyl cyclase (sGC) which consists of α 1 -and β 1 -subunits and catalyzes the production of cGMP upon stimulation with nitric oxide (NO). cGMP acts a second messenger that mediates diverse cellular functions, e.g. smooth muscle relaxation and inhibition of platelet aggregation. Using wholeexome sequencing, our group also identified nine rare variants in the coding sequence of GUCY1A3 [2] . Two of these variants were found in two extended families with a high prevalence of premature CAD/MI. Seven further rare variants were found in 252 young MI patients. In this study, we aimed to investigate the functional implication of these rare variants found in CAD/MI patients (Table 1 ) regarding protein level, dimerization capability and enzymatic activity.
Two of the investigated α 1 variants exhibited significantly decreased protein levels compared to wild type α 1 . The amount of β 1 correlated with those of α 1 in all cases. All α 1 variants, except for p.Leu163Phefs*24, still dimerized with the β 1 subunit, as shown by co-immunoprecipitation. Using radioimmunoassay three of the rare variants demonstrated significantly decreased cGMP amounts at every time point tested (0.5/1/2 min). The activity only in part correlated with the observed protein levels pointing to an effect of the tested variants on enzymatic activity. As we have shown that loss of function-mutations in GUCY1A3 may lead to CAD/MI [2] , decreased enzymatic activity might also increase risk. 
